Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Zhaoke Ophthalmology Limited has announced positive top-line results from the Phase III clinical trial of TAB014, a treatment for wet age-related macular degeneration (wAMD), which met its primary and key secondary endpoints. TAB014 is positioned as a cost-effective solution in a rapidly growing market and marks a significant step forward in ophthalmic treatment innovations in China. The company has secured full control over the clinical development and commercialization of TAB014 in China, Hong Kong, and Macau through an agreement with TOT BIOPHARM.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Amazon’s (NASDAQ:AMZN) Return-to-Office Mandate Comes With Unexpected Issue
- Ford (NYSE:F) Bonds Prove Tempting, Fuel Pumps Less So
- Intel (NASDAQ:INTC) Augments LG Laptops, Faces Challenges
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
%20CGM%20Gets%20FDA's%20Breakthrough%20Device%20Designation%20%7C%20Nasdaq&_biz_n=2&rnd=775791&cdn_o=a&_biz_z=1743104348021)
